_id
690da886ccc777a4e85d07ea
Ticker
ABVX
Name
Abivax SA American Depositary Shares
Exchange
NASDAQ
Address
7-11 boulevard Haussmann, Paris, France, 75009
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.abivax.com
Description
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Last Close
119.99
Volume
571736
Current Price
117.75
Change
-1.09
Last Updated
2026-01-21T19:23:30.614Z
Image
data:image/webp;base64,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
Ipo Date
2023-10-20T00:00:00.000Z
Market Cap
8187961856
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.8679428571428571
Sentiment Sources
21
Rating
4.4286
Target Price
123.7778
Strong Buy
4
Buy
2
Hold
1
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
80712000
Operating Income
-80712000
Interest Expense
4213000
Pretax Income
-153358000
Net Income
-153358000
Eps
-1.97042101993822
Dividends Per Share
0
Shares Outstanding
77828918
Income Tax Expense
-
EBITDA
-
Operating Margin
-
Total Other Income Expense Net
-23502000
Cash
589703000
Short Term Investments
-
Receivables
-
Inventories
-
Total Current Assets
619295000
Property Plant Equipment
1914000
Total Assets
652052000
Payables
14355000
Short Term Debt
-
Long Term Debt
15878000
Total Liabilities
140814000
Equity
511238000
Bs_currency_symbol
EUR
Depreciation
272000
Change In Working Capital
-2075000
Cash From Operations
-71283000
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
603460000
Net Change In Cash
528756000
Cf_currency_symbol
EUR
PE
-
PB
17.926074331818057
ROE
-29.997378911583255
ROA
-23.51928987258685
FCF
-71283000
Fcf Percent
-
Piotroski FScore
1
Health Score
27
Deep Value Investing Score
3.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
5.3
Garp Investing Score
2.5
Growth Investing Score
1
Momentum Investing Score
4
Net Net Investing Score
2.5
Quality Investing Score
3
Value Investing Score
5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
80712000
Quarters > 0 > income Statement > operating Income
-80712000
Quarters > 0 > income Statement > interest Expense
4213000
Quarters > 0 > income Statement > pretax Income
-153358000
Quarters > 0 > income Statement > net Income
-153358000
Quarters > 0 > income Statement > eps
-1.97042101993822
Quarters > 0 > income Statement > dividends Per Share
0
Quarters > 0 > income Statement > shares Outstanding
77830067
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-23502000
Quarters > 0 > income Statement > currency_symbol
EUR
Quarters > 0 > balance Sheet > cash
589703000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
619295000
Quarters > 0 > balance Sheet > property Plant Equipment
1914000
Quarters > 0 > balance Sheet > total Assets
652052000
Quarters > 0 > balance Sheet > payables
14355000
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
15878000
Quarters > 0 > balance Sheet > total Liabilities
140814000
Quarters > 0 > balance Sheet > equity
511238000
Quarters > 0 > balance Sheet > currency_symbol
EUR
Quarters > 0 > cash Flow > net Income
-153358000
Quarters > 0 > cash Flow > depreciation
272000
Quarters > 0 > cash Flow > change In Working Capital
-2075000
Quarters > 0 > cash Flow > cash From Operations
-71283000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
603460000
Quarters > 0 > cash Flow > net Change In Cash
528756000
Quarters > 0 > cash Flow > currency_symbol
EUR
Quarters > 0 > ratios > PE
-1.97042101993822
Quarters > 0 > ratios > PB
17.926074331818057
Quarters > 0 > ratios > ROE
-29.997378911583255
Quarters > 0 > ratios > ROA
-23.51928987258685
Quarters > 0 > ratios > FCF
-71283000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
27
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
2017000
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
2017000
Quarters > 1 > income Statement > operating Expenses
95713000
Quarters > 1 > income Statement > operating Income
-93696000
Quarters > 1 > income Statement > interest Expense
7007000
Quarters > 1 > income Statement > pretax Income
-100784000
Quarters > 1 > income Statement > net Income
-100784000
Quarters > 1 > income Statement > eps
-1.5894101229452509
Quarters > 1 > income Statement > dividends Per Share
0
Quarters > 1 > income Statement > shares Outstanding
63409688
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-93594000
Quarters > 1 > income Statement > operating Margin
-4645.314823996034
Quarters > 1 > income Statement > total Other Income Expense Net
-7088000
Quarters > 1 > income Statement > currency_symbol
EUR
Quarters > 1 > balance Sheet > cash
60946000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
14737000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
86102000
Quarters > 1 > balance Sheet > property Plant Equipment
2159000
Quarters > 1 > balance Sheet > total Assets
119641000
Quarters > 1 > balance Sheet > payables
36114000
Quarters > 1 > balance Sheet > short Term Debt
48843000
Quarters > 1 > balance Sheet > long Term Debt
34782000
Quarters > 1 > balance Sheet > total Liabilities
167921000
Quarters > 1 > balance Sheet > equity
-48280000
Quarters > 1 > balance Sheet > currency_symbol
EUR
Quarters > 1 > cash Flow > net Income
-100784000
Quarters > 1 > cash Flow > depreciation
524000
Quarters > 1 > cash Flow > change In Working Capital
2287000
Quarters > 1 > cash Flow > cash From Operations
-66617999
Quarters > 1 > cash Flow > capital Expenditures
63000
Quarters > 1 > cash Flow > cash From Investing
1269000
Quarters > 1 > cash Flow > cash From Financing
-8767000
Quarters > 1 > cash Flow > net Change In Cash
60946000
Quarters > 1 > cash Flow > currency_symbol
EUR
Quarters > 1 > ratios > PE
-1.5894101229452509
Quarters > 1 > ratios > PB
-154.6497672328086
Quarters > 1 > ratios > ROE
208.7489643744822
Quarters > 1 > ratios > ROA
-84.23868071982012
Quarters > 1 > ratios > FCF
-66680999
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-33.059493802677245
Quarters > 1 > health Score
31
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
47200000
Quarters > 2 > income Statement > operating Income
-47200000
Quarters > 2 > income Statement > interest Expense
4535000
Quarters > 2 > income Statement > pretax Income
-52370000
Quarters > 2 > income Statement > net Income
-52370000
Quarters > 2 > income Statement > eps
-0.8257810320414867
Quarters > 2 > income Statement > dividends Per Share
0
Quarters > 2 > income Statement > shares Outstanding
63418749
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-904000
Quarters > 2 > income Statement > currency_symbol
EUR
Quarters > 2 > balance Sheet > cash
103576000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
132667000
Quarters > 2 > balance Sheet > property Plant Equipment
2410000
Quarters > 2 > balance Sheet > total Assets
166939000
Quarters > 2 > balance Sheet > payables
56525000
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
47001000
Quarters > 2 > balance Sheet > total Liabilities
173532000
Quarters > 2 > balance Sheet > equity
-6593000
Quarters > 2 > balance Sheet > currency_symbol
EUR
Quarters > 2 > cash Flow > net Income
-52400000
Quarters > 2 > cash Flow > depreciation
273000
Quarters > 2 > cash Flow > change In Working Capital
9011000
Quarters > 2 > cash Flow > cash From Operations
-33278000
Quarters > 2 > cash Flow > capital Expenditures
44000
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
-7838000
Quarters > 2 > cash Flow > net Change In Cash
-40646000
Quarters > 2 > cash Flow > currency_symbol
EUR
Quarters > 2 > ratios > PE
-0.8257810320414867
Quarters > 2 > ratios > PB
-1132.6494304186258
Quarters > 2 > ratios > ROE
794.3273168512059
Quarters > 2 > ratios > ROA
-31.370740210496052
Quarters > 2 > ratios > FCF
-33322000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
30
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
7399000
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
7399000
Quarters > 3 > income Statement > operating Expenses
140384500
Quarters > 3 > income Statement > operating Income
-132985500
Quarters > 3 > income Statement > interest Expense
1372000
Quarters > 3 > income Statement > pretax Income
-94604000
Quarters > 3 > income Statement > net Income
-94604000
Quarters > 3 > income Statement > eps
-1.4975148003925665
Quarters > 3 > income Statement > dividends Per Share
0
Quarters > 3 > income Statement > shares Outstanding
63174000
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-131970500
Quarters > 3 > income Statement > operating Margin
-1797.3442357075282
Quarters > 3 > income Statement > total Other Income Expense Net
38381500
Quarters > 3 > income Statement > currency_symbol
EUR
Quarters > 3 > balance Sheet > cash
144221000
Quarters > 3 > balance Sheet > short Term Investments
136000
Quarters > 3 > balance Sheet > receivables
15663000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
170671000
Quarters > 3 > balance Sheet > property Plant Equipment
2666000
Quarters > 3 > balance Sheet > total Assets
205228000
Quarters > 3 > balance Sheet > payables
43824000
Quarters > 3 > balance Sheet > short Term Debt
43769000
Quarters > 3 > balance Sheet > long Term Debt
52161000
Quarters > 3 > balance Sheet > total Liabilities
164644000
Quarters > 3 > balance Sheet > equity
40584000
Quarters > 3 > balance Sheet > currency_symbol
EUR
Quarters > 3 > cash Flow > net Income
-94604000
Quarters > 3 > cash Flow > depreciation
262000
Quarters > 3 > cash Flow > change In Working Capital
568000
Quarters > 3 > cash Flow > cash From Operations
-68897000
Quarters > 3 > cash Flow > capital Expenditures
202000
Quarters > 3 > cash Flow > cash From Investing
1152000
Quarters > 3 > cash Flow > cash From Financing
-12115000
Quarters > 3 > cash Flow > net Change In Cash
-36229000
Quarters > 3 > cash Flow > currency_symbol
EUR
Quarters > 3 > ratios > PE
-1.4975148003925665
Quarters > 3 > ratios > PB
183.29239355411
Quarters > 3 > ratios > ROE
-233.10664301202445
Quarters > 3 > ratios > ROA
-46.09702379792231
Quarters > 3 > ratios > FCF
-69099000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-9.338964724962834
Quarters > 3 > health Score
8
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
10792000
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
10792000
Annuals > 0 > income Statement > operating Expenses
183776000
Annuals > 0 > income Statement > operating Income
-172984000
Annuals > 0 > income Statement > interest Expense
4184999
Annuals > 0 > income Statement > pretax Income
-176242000
Annuals > 0 > income Statement > net Income
-176242000
Annuals > 0 > income Statement > eps
-2.7954509405830663
Annuals > 0 > income Statement > dividends Per Share
0
Annuals > 0 > income Statement > shares Outstanding
63046000
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-171883000
Annuals > 0 > income Statement > operating Margin
-1602.8910303928835
Annuals > 0 > income Statement > total Other Income Expense Net
-3258000
Annuals > 0 > income Statement > currency_symbol
EUR
Annuals > 0 > balance Sheet > cash
144221000
Annuals > 0 > balance Sheet > short Term Investments
136000
Annuals > 0 > balance Sheet > receivables
15663000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
170671000
Annuals > 0 > balance Sheet > property Plant Equipment
2665000
Annuals > 0 > balance Sheet > total Assets
205228000
Annuals > 0 > balance Sheet > payables
43824000
Annuals > 0 > balance Sheet > short Term Debt
43769000
Annuals > 0 > balance Sheet > long Term Debt
52161000
Annuals > 0 > balance Sheet > total Liabilities
164644000
Annuals > 0 > balance Sheet > equity
40584000
Annuals > 0 > balance Sheet > currency_symbol
EUR
Annuals > 0 > cash Flow > net Income
-176242000
Annuals > 0 > cash Flow > depreciation
1100000
Annuals > 0 > cash Flow > change In Working Capital
1423000
Annuals > 0 > cash Flow > cash From Operations
-154072000
Annuals > 0 > cash Flow > capital Expenditures
643000
Annuals > 0 > cash Flow > cash From Investing
15762000
Annuals > 0 > cash Flow > cash From Financing
28207000
Annuals > 0 > cash Flow > net Change In Cash
-107721000
Annuals > 0 > cash Flow > currency_symbol
EUR
Annuals > 0 > ratios > PE
-2.7954509405830663
Annuals > 0 > ratios > PB
182.92101567120045
Annuals > 0 > ratios > ROE
-434.26473487088504
Annuals > 0 > ratios > ROA
-85.87619623053384
Annuals > 0 > ratios > FCF
-154715000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-14.33608228317272
Annuals > 0 > health Score
8
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
4621000
Annuals > 1 > income Statement > cost Of Revenue
707000
Annuals > 1 > income Statement > gross Profit
4574000
Annuals > 1 > income Statement > operating Expenses
127376000
Annuals > 1 > income Statement > operating Income
-127376000
Annuals > 1 > income Statement > interest Expense
13826000
Annuals > 1 > income Statement > pretax Income
-152233000
Annuals > 1 > income Statement > net Income
-147740000
Annuals > 1 > income Statement > eps
-3.4305484605024845
Annuals > 1 > income Statement > dividends Per Share
0
Annuals > 1 > income Statement > shares Outstanding
43066000
Annuals > 1 > income Statement > income Tax Expense
-4493000
Annuals > 1 > income Statement > EBITDA
-133207000
Annuals > 1 > income Statement > operating Margin
-2756.4596407703957
Annuals > 1 > income Statement > total Other Income Expense Net
-20364000
Annuals > 1 > income Statement > currency_symbol
EUR
Annuals > 1 > balance Sheet > cash
251942000
Annuals > 1 > balance Sheet > short Term Investments
9050000
Annuals > 1 > balance Sheet > receivables
19099000
Annuals > 1 > balance Sheet > inventories
-5882000
Annuals > 1 > balance Sheet > total Current Assets
285972000
Annuals > 1 > balance Sheet > property Plant Equipment
877000
Annuals > 1 > balance Sheet > total Assets
327062000
Annuals > 1 > balance Sheet > payables
47221000
Annuals > 1 > balance Sheet > short Term Debt
31260000
Annuals > 1 > balance Sheet > long Term Debt
44697000
Annuals > 1 > balance Sheet > total Liabilities
131052000
Annuals > 1 > balance Sheet > equity
196010000
Annuals > 1 > balance Sheet > currency_symbol
EUR
Annuals > 1 > cash Flow > net Income
-147740000
Annuals > 1 > cash Flow > depreciation
707000
Annuals > 1 > cash Flow > change In Working Capital
21266000
Annuals > 1 > cash Flow > cash From Operations
-100009000
Annuals > 1 > cash Flow > capital Expenditures
265000
Annuals > 1 > cash Flow > cash From Investing
-10495000
Annuals > 1 > cash Flow > cash From Financing
340569000
Annuals > 1 > cash Flow > net Change In Cash
224992000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
-3.4305484605024845
Annuals > 1 > ratios > PB
25.871238712310596
Annuals > 1 > ratios > ROE
-75.37370542319269
Annuals > 1 > ratios > ROA
-45.17186343873639
Annuals > 1 > ratios > FCF
-100274000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-21.699632114260982
Annuals > 1 > health Score
22
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
4583000
Annuals > 2 > income Statement > cost Of Revenue
110000
Annuals > 2 > income Statement > gross Profit
4473000
Annuals > 2 > income Statement > operating Expenses
56537000
Annuals > 2 > income Statement > operating Income
-64836000
Annuals > 2 > income Statement > interest Expense
6940000
Annuals > 2 > income Statement > pretax Income
-74323000
Annuals > 2 > income Statement > net Income
-60740000
Annuals > 2 > income Statement > eps
-3.181437251204693
Annuals > 2 > income Statement > dividends Per Share
0
Annuals > 2 > income Statement > shares Outstanding
19092000
Annuals > 2 > income Statement > income Tax Expense
-4476000
Annuals > 2 > income Statement > EBITDA
-53315000
Annuals > 2 > income Statement > operating Margin
-1414.7065241108444
Annuals > 2 > income Statement > total Other Income Expense Net
4096000
Annuals > 2 > income Statement > currency_symbol
EUR
Annuals > 2 > balance Sheet > cash
26950000
Annuals > 2 > balance Sheet > short Term Investments
6000
Annuals > 2 > balance Sheet > receivables
8316000
Annuals > 2 > balance Sheet > inventories
12187000
Annuals > 2 > balance Sheet > total Current Assets
36181000
Annuals > 2 > balance Sheet > property Plant Equipment
1592000
Annuals > 2 > balance Sheet > total Assets
75544000
Annuals > 2 > balance Sheet > payables
15475000
Annuals > 2 > balance Sheet > short Term Debt
30034000
Annuals > 2 > balance Sheet > long Term Debt
36575000
Annuals > 2 > balance Sheet > total Liabilities
68355000
Annuals > 2 > balance Sheet > equity
7189000
Annuals > 2 > balance Sheet > currency_symbol
EUR
Annuals > 2 > cash Flow > net Income
-60740000
Annuals > 2 > cash Flow > depreciation
485000
Annuals > 2 > cash Flow > change In Working Capital
-2002000
Annuals > 2 > cash Flow > cash From Operations
-53936000
Annuals > 2 > cash Flow > capital Expenditures
323000
Annuals > 2 > cash Flow > cash From Investing
-12026000
Annuals > 2 > cash Flow > cash From Financing
32211000
Annuals > 2 > cash Flow > net Change In Cash
-33751000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
-3.181437251204693
Annuals > 2 > ratios > PB
312.7115036861872
Annuals > 2 > ratios > ROE
-844.9019335095285
Annuals > 2 > ratios > ROA
-80.40347347241342
Annuals > 2 > ratios > FCF
-54259000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-11.83918830460397
Annuals > 2 > health Score
8
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
37000
Annuals > 3 > income Statement > cost Of Revenue
156000
Annuals > 3 > income Statement > gross Profit
-119000
Annuals > 3 > income Statement > operating Expenses
42597000
Annuals > 3 > income Statement > operating Income
-41400000
Annuals > 3 > income Statement > interest Expense
3558000
Annuals > 3 > income Statement > pretax Income
-42452000
Annuals > 3 > income Statement > net Income
-42452000
Annuals > 3 > income Statement > eps
-2.7466356107660457
Annuals > 3 > income Statement > dividends Per Share
0
Annuals > 3 > income Statement > shares Outstanding
15456000
Annuals > 3 > income Statement > income Tax Expense
-4204000
Annuals > 3 > income Statement > EBITDA
-38592000
Annuals > 3 > income Statement > operating Margin
-111891.8918918919
Annuals > 3 > income Statement > total Other Income Expense Net
-1052000
Annuals > 3 > income Statement > currency_symbol
EUR
Annuals > 3 > balance Sheet > cash
60695000
Annuals > 3 > balance Sheet > short Term Investments
6000
Annuals > 3 > balance Sheet > receivables
8339000
Annuals > 3 > balance Sheet > inventories
4000000
Annuals > 3 > balance Sheet > total Current Assets
75212000
Annuals > 3 > balance Sheet > property Plant Equipment
93000
Annuals > 3 > balance Sheet > total Assets
109230000
Annuals > 3 > balance Sheet > payables
18558000
Annuals > 3 > balance Sheet > short Term Debt
10232000
Annuals > 3 > balance Sheet > long Term Debt
53445000
Annuals > 3 > balance Sheet > total Liabilities
83297000
Annuals > 3 > balance Sheet > equity
25933000
Annuals > 3 > balance Sheet > currency_symbol
EUR
Annuals > 3 > cash Flow > net Income
-42560000
Annuals > 3 > cash Flow > depreciation
156000
Annuals > 3 > cash Flow > change In Working Capital
-668000
Annuals > 3 > cash Flow > cash From Operations
-45657000
Annuals > 3 > cash Flow > capital Expenditures
1642000
Annuals > 3 > cash Flow > cash From Investing
-1456000
Annuals > 3 > cash Flow > cash From Financing
78512000
Annuals > 3 > cash Flow > net Change In Cash
31399000
Annuals > 3 > cash Flow > currency_symbol
EUR
Annuals > 3 > ratios > PE
-2.7466356107660457
Annuals > 3 > ratios > PB
70.17869124281803
Annuals > 3 > ratios > ROE
-163.69876219488683
Annuals > 3 > ratios > ROA
-38.86478073789252
Annuals > 3 > ratios > FCF
-47299000
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-1278.3513513513512
Annuals > 3 > health Score
9
Valuation > metrics > PE
-1.97042101993822
Valuation > metrics > PB
17.926074331818057
Valuation > final Score
20
Valuation > verdict
497.5% Overvalued
Profitability > metrics > ROE
-29.997378911583255
Profitability > metrics > ROA
-24.763319581136614
Profitability > metrics > Net Margin
-
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.2754372718772861
Risk > metrics > Interest Coverage
-19.157844766199858
Risk > final Score
-17
Risk > verdict
High
Liquidity > metrics > Current Ratio
43.14141414141414
Liquidity > metrics > Quick Ratio
43.14141414141414
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
20
Prev Profitabilities > 0
40
Prev Profitabilities > 1
40
Prev Profitabilities > 2
0
Prev Risks > 0
-23
Prev Risks > 1
-12
Prev Risks > 2
-382
Prev Liquidities > 0
50
Prev Liquidities > 1
100
Prev Liquidities > 2
50
Updated At
2026-01-21T19:23:31.634Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-23
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-09-30
Earnings History > 1 > report Date
2025-12-15
Earnings History > 1 > date
2025-09-30
Earnings History > 1 > before After Market
AfterMarket
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-2.47
Earnings History > 1 > eps Estimate
-0.79
Earnings History > 1 > eps Difference
-1.68
Earnings History > 1 > surprise Percent
-212.6582
Earnings History > 2 > period
2025-06-30
Earnings History > 2 > report Date
2025-09-08
Earnings History > 2 > date
2025-06-30
Earnings History > 2 > before After Market
AfterMarket
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.89
Earnings History > 2 > eps Estimate
-0.95
Earnings History > 2 > eps Difference
0.06
Earnings History > 2 > surprise Percent
6.3158
Earnings History > 3 > period
2025-03-31
Earnings History > 3 > report Date
2025-06-02
Earnings History > 3 > date
2025-03-31
Earnings History > 3 > before After Market
AfterMarket
Earnings History > 3 > currency
EUR
Earnings History > 3 > eps Actual
-0.95
Earnings History > 3 > eps Estimate
-0.76
Earnings History > 3 > eps Difference
-0.19
Earnings History > 3 > surprise Percent
-25
Earnings History > 4 > period
2024-12-31
Earnings History > 4 > report Date
2025-03-24
Earnings History > 4 > date
2024-12-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
-
Earnings History > 4 > eps Actual
-0.8143
Earnings History > 4 > eps Estimate
-1.29
Earnings History > 4 > eps Difference
0.4757
Earnings History > 4 > surprise Percent
36.876
Earnings History > 5 > period
2024-09-30
Earnings History > 5 > report Date
2024-11-07
Earnings History > 5 > date
2024-09-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
-
Earnings History > 5 > eps Actual
-0.72
Earnings History > 5 > eps Estimate
-0.79
Earnings History > 5 > eps Difference
0.07
Earnings History > 5 > surprise Percent
8.8608
Earnings History > 6 > period
2024-06-30
Earnings History > 6 > report Date
2024-09-09
Earnings History > 6 > date
2024-06-30
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
-
Earnings History > 6 > eps Actual
-1.01
Earnings History > 6 > eps Estimate
-0.97
Earnings History > 6 > eps Difference
-0.04
Earnings History > 6 > surprise Percent
-4.1237
Earnings History > 7 > period
2024-03-31
Earnings History > 7 > report Date
2024-04-02
Earnings History > 7 > date
2024-03-31
Earnings History > 7 > before After Market
BeforeMarket
Earnings History > 7 > currency
EUR
Earnings History > 7 > eps Actual
-0.7903
Earnings History > 7 > eps Estimate
-0.6
Earnings History > 7 > eps Difference
-0.1903
Earnings History > 7 > surprise Percent
-31.7167
Earnings History > 8 > period
2023-12-31
Earnings History > 8 > report Date
2024-02-06
Earnings History > 8 > date
2023-12-31
Earnings History > 8 > before After Market
AfterMarket
Earnings History > 8 > currency
EUR
Earnings History > 8 > eps Actual
0
Earnings History > 8 > eps Estimate
-0.92
Earnings History > 8 > eps Difference
0.92
Earnings History > 8 > surprise Percent
100
Earnings History > 9 > period
2023-09-30
Earnings History > 9 > report Date
2023-11-29
Earnings History > 9 > date
2023-09-30
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
EUR
Earnings History > 9 > eps Actual
-0.64
Earnings History > 9 > eps Estimate
-0.64
Earnings History > 9 > eps Difference
0
Earnings History > 9 > surprise Percent
0
Earnings History > 10 > period
2023-06-30
Earnings History > 10 > report Date
2023-09-21
Earnings History > 10 > date
2023-06-30
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
EUR
Earnings History > 10 > eps Actual
-0.72
Earnings History > 10 > eps Estimate
0
Earnings History > 10 > eps Difference
-0.72
Earnings History > 10 > surprise Percent
-
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AShowing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$123.7778
Analyst Picks
Strong Buy
4
Buy
2
Hold
1
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Abivax SA American Depositary Shares
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
2025-09-30
EPS Actual
-2.47
EPS Estimate
-0.79
EPS Difference
-1.68
Surprise Percent
-212.6582%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.